Rutherford, G. W., & Horvath, H. (2016). Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review. PLoS One.
Citación estilo ChicagoRutherford, George W., and Hacsi Horvath. "Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors Versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People With HIV: A Systematic Review." PLoS One 2016.
Cita MLARutherford, George W., and Hacsi Horvath. "Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors Versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People With HIV: A Systematic Review." PLoS One 2016.